A key mechanism that fuels uncontrolled cell growth is uncovered in yeast

Scientists have long wondered how cancer cells use a protein complex, called TOR, to survive and proliferate in nutrient-poor conditions. Now, CCR researchers have discovered how a protein that is targeted by TOR drives this process, which holds important implications for understanding cancer and some genetic disorders. Read more...

Immunotherapy cells

In mice, new therapeutic strategy enhances the effects of immunotherapy in high ASS1-expressing cancers

Aug 31, 2020

Many prevalent cancers (e.g., lung, breast and colon) exhibit abnormally high expression of the enzyme ASS1. This results in greater production of genetic material incorporating purines, consequently making these tumors more resistant to immunotherapy. The researchers showed that drugs blocking purine production in these tumors enhance their response to immunotherapy. Read more...


Our leukemia and lymphoma research

Aug 27, 2020

September is leukemia and lymphoma awareness month. Lymphoma is a broad term for cancer that begins in cells of the lymph system. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Leukemia is a broad term for cancers of the blood cells. The type of leukemia depends on the type of blood cell that becomes cancer and whether it grows quickly or slowly. To learn more about our leukemia and lymphoma research, click here.

SARS-CoV-2 virus

Experimental compound blocks SARS-CoV-2’s ability to infect and kill cells in the lab

Aug 25, 2020

A potential therapy for COVID-19 binds to a viral enzyme that SARS-CoV-2 requires for replication. With further development and testing, it might be an effective treatment for people with the disease. Read more...

TILs in culture

Clinical trial studies three immunotherapies given before surgery in newly diagnosed head and neck cancers not caused by HPV

Aug 20, 2020

Newly diagnosed head and neck cancer not caused by HPV infection often uses surgery as the first treatment. After surgery, about half of patients with head and neck squamous cell carcinoma (HNSCC) that was not caused by the human papillomavirus (HPV) will have disease relapse within two years. Jason Redman, M.D., Assistant Research Physician in the Genitourinary Malignancies Branch, is leading a trial of three proposed immunotherapy treatments given before surgery for HNSCC. Read more...

Breast cancer cells

Epigenetic marker contributes to PARP inhibitor resistance

Aug 19, 2020

CCR scientists have discovered a way cancer cells can become resistant to PARP inhibitors, targeted therapies that are used to treat some ovarian, breast and prostate cancers. Read more...

RNA strand

New synthetic compounds alter RNA expression in bacteria

Aug 18, 2020

Researchers have succeeded in developing a number of different compounds that bind to ZTP riboswitches, which regulate RNA, in bacteria. Their approach could one day be used to create a new class of antibacterial drug. Read more...

Adam Sowalsky, Ph.D.

A Conversation with Adam Sowalsky, Ph.D.

Aug 4, 2020

Adam Sowalsky, Ph.D., is an Investigator in the Laboratory of Genitourinary Cancer Pathogenesis. He is seeking to tease apart the molecular mechanisms underlying prostate cancers that have a high likelihood of progressing and then identifying patients who might benefit from earlier therapy. He discusses what motivated him to pursue a career in cancer biology as well as what lies ahead for his research. Read more...

Patient scan

Clinical trial evaluates radiopharmaceutical as therapy for biochemically recurrent prostate cancer

Jul 28, 2020

Some men who have been treated for localized prostate cancer (PC) with surgery or radiation still have signs of the disease that are only detected by a blood test (a rising prostate specific antigen or PSA). This is called biochemically recurrent prostate cancer (BCRpc). Investigators in the Center for Cancer Research are leading a clinical trial exploring an option meant to be less toxic for treating BCRpc, which may impact microscopic bone disease seen only on PET scans, using radium-223. Read more...

Liver tumor

Immunotherapy clinical trial tests therapy for metastatic solid tumors

Jul 17, 2020

Tumor-infiltrating lymphocytes (TILs) are white blood cells (T cells) that have moved from the blood into a tumor. While tumor cells frequently change their molecular structure to avoid attack by the immune system’s T cells, recent studies by the Center for Cancer Research’s Surgery Branch have found that most TILs don’t recognize newly mutated tumor cells. A clinical trial led by Steve Rosenberg, M.D., Ph.D., engineers T cells to recognize newly altered cancer cells that are then given back to the patient to help the immune system kill cancer cells in solid tumors. Read more...

Amy Toner and Audra Addison

Two patient’s stomachs kept “alive” after removal in novel study to understand stomach cancer

Jul 15, 2020

Two women with genetic predisposition to stomach cancer participated in a clinical trial at the Center for Cancer Research where their stomachs were removed and kept “alive” for several days, allowing the researchers to study the development of cancer and the effects of different therapies in unprecedented detail. The goal is to better study stomach cancer under realistic conditions and find novel, effective treatments. Read more...